(NASDAQ: HYFT) Mindwalk Holdings's forecast annual revenue growth rate of 35.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Mindwalk Holdings's revenue in 2025 is $16,244,927.On average, 4 Wall Street analysts forecast HYFT's revenue for 2026 to be $840,374,181, with the lowest HYFT revenue forecast at $619,665,188, and the highest HYFT revenue forecast at $1,066,252,434. On average, 3 Wall Street analysts forecast HYFT's revenue for 2027 to be $1,443,562,349, with the lowest HYFT revenue forecast at $1,386,977,400, and the highest HYFT revenue forecast at $1,486,024,137.
In 2028, HYFT is forecast to generate $1,846,164,720 in revenue, with the lowest revenue forecast at $1,773,748,909 and the highest revenue forecast at $1,900,441,963.